#USA #London #OncoBayes #OB-001 #ADC resistance

OncoBayes Moves Forward with OB-001

OncoBayes, a clinical-stage pharmaceutical firm, has made an important announcement regarding the advancement of its innovative treatment, OB-001. Recently, the company revealed that it has successfully finalized its preclinical studies, showcasing OB-001's potential in tackling significant challenges within oncology. These challenges largely include antibody-drug conjugate (ADC) resistance and the penetration of tyrosine kinase inhibitors (TKIs) into the brain, both critical areas of unmet need in cancer treatment.

Breakthroughs in Preclinical Research

OB-001 is positioned as a highly selective and efficient inhibitor targeting two prominent efflux pumps, P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). These pumps are significant barriers on the blood-brain barrier and can hinder effective treatment delivery in tumors. The drug is planned for administration as a once-daily oral tablet, designed to be combined with standard oncology therapies to enhance their effectiveness.

In studies involving perfused-brain mouse models, pretreatment with OB-001 notably increased the brain exposure levels for four leading kinase inhibitors. Notably, the systemic exposure—meaning the levels present in plasma—remained largely unchanged. Findings presented at the AACR 2026 conference reveal that OB-001 can boost brain exposure to osimertinib by nearly 400% while causing minimal changes in systemic circulation. This substantial enhancement in brain concentration is anticipated to improve progression-free survival rates for patients with non-small cell lung cancer (NSCLC) featuring EGFR mutations, especially regarding managing brain metastases, a persistent challenge in NSCLC and breast cancer.

Addressing ADC Resistance

The same efflux pumps responsible for the resistance to TKIs also play a critical role in ADC treatment failure. Their overexpression results in lower payload concentrations within tumors, limiting the effectiveness of these therapies. Preclinical data indicates that OB-001 can significantly reduce the efflux of various leading cancer treatment payloads, including SN-38 (found in drugs such as sacituzumab govitecan), DM4 (as in mirvetuximab soravtansine), and DXd (utilized in trastuzumab deruxtecan).

OncoBayes is gearing up to initiate a clinical trial program that will generate proof-of-concept (POC) data by evaluating OB-001 in combination with osimertinib. There are also plans to assess the re-sensitization effect of drug combinations including T-DXd, marking a pivotal step in the development of treatments tackling ADC resistance.

OncoBayes' Commitment to Innovation

Jim Millen, the CEO of OncoBayes, expressed pride in reaching this critical milestone, stating, “We are well-positioned to embark on our clinical plans with OB-001. This compound is on track to become a first-in-class treatment that serves a broad market as a simple oral adjunct to numerous successful oncology therapies. The pipeline is proving to be a remarkable opportunity.”

With the promising results from preclinical investigations and a strategic plan for clinical trials, OncoBayes continues to carve its path in oncology, aiming to offer innovative solutions that address complex treatment barriers. The ongoing research and anticipated clinical trials will be pivotal in bringing OB-001 closer to the patients who need effective therapies against challenging cancers.

The journey of OB-001 represents hope for patients battling cancers affected by ADC resistance and inadequate drug penetration, symbolizing a future where effective treatment solutions may soon be at hand.